Actively Recruiting
Comparing Non-TNFi Biologic and Targeted Synthetic DMARD Treatments for Active Rheumatoid Arthritis Despite TNFi Therapy
Led by University of Alabama at Birmingham · Updated on 2026-09-24
924
Participants Needed
49
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating treatment options for people with active rheumatoid arthritis RA who have not responded well to a tumor necrosis factor inhibitor TNFi biologic medication. The study compares two treatment strategies switching to a non-TNFi biologic drug such as rituximab, abatacept, tocilizumab, or sarilumab versus switching to a targeted synthetic disease-modifying antirheumatic drug tsDMARD like tofacitinib, baricitinib, or upadacitinib. This research addresses a significant gap in knowledge as current guidelines recommend switching treatments but lack strong evidence comparing these options directly, especially regarding patient-reported outcomes PROs like function and quality of life. Participants will be randomly assigned to receive either a non-TNFi biologic or a targeted synthetic DMARD. The choice of specific medication within each class is based on what is available and accessible through insurance or patient assistance programs. The study follows a pragmatic design to reflect real-world treatment decisions and includes patients with comorbidities. Treatment continues with stable doses of certain conventional synthetic DMARDs if already being used. This head-to-head trial aims to provide comparative effectiveness data for these two treatment strategies over a 12-month period. During the trial, participants will be monitored for changes in functional limitations using the Health Assessment Questionnaire HAQ, a sensitive tool for measuring outcomes important to patients with RA. Researchers will also track treatment toxicity and quality of life changes. The study involves regular assessments over one year to evaluate the benefits and risks of each treatment approach, helping patients and providers make informed decisions based on outcomes that matter most to patients.
CONDITIONS
Brief Title
RA-PRO PRAGMATIC TRIAL
Research Team
J
Jasvinder Singh
C
Clementino Vong Do Rosario, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here